Monobactam Synthesis via Dynamic Kinetic Resolution

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current processes for producing monobactam antibiotic Compound X are inefficient due to numerous steps, nitrogen protection/deprotection steps, and the need for chromatographic purification, resulting in poor handling characteristics and low yield.

Innovation Solution

A new process that eliminates the need for nitrogen protecting groups in the final synthesis steps, reducing the number of purification steps and improving handling characteristics by reacting compounds of formulas 22 and 2A in a solvent with a base and coupling agent, and employing asymmetric reduction conditions for intermediate synthesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional processes are used for producing monobactam antibiotic Compound X, then the synthesis can be completed with established methods, but the process requires numerous steps including nitrogen protection/deprotection and chromatographic purification, resulting in low yield and poor handling characteristics

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidnumber of process steps
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The invention extracts and eliminates the nitrogen protection/deprotection steps from the conventional synthesis process. By using alternative reaction conditions and reagents, the process directly synthesizes the final compound without requiring intermediate protection groups, thereby reducing the number of process steps and improving overall yield while maintaining product purity

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention implements continuous synthesis by eliminating discrete protection and deprotection cycles. The reaction sequence proceeds continuously through fewer intermediate stages, with each step building directly toward the final product without interruption for protecting group manipulation, thereby improving productivity and reducing process complexity

Inventive Principle:
Principle #20Continuity of useful action

2Stability of the object's composition

If conventional processes with nitrogen protecting groups are used, then intermediate stability can be maintained, but the need for multiple purification steps increases process complexity and reduces yield

Engineering Contradiction:
Improveintermediate stabilityVSAvoidpurification steps
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The invention removes the requirement for nitrogen protecting groups entirely from the synthesis pathway. By selecting reaction conditions that maintain intermediate stability without protection groups, the process eliminates the need for multiple chromatographic purification steps, thereby reducing process complexity while preserving intermediate integrity

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the reaction parameters (such as solvent selection, temperature control, and reagent choice) to enable stable intermediate formation without nitrogen protection groups. This parameter optimization allows the synthesis to proceed through fewer purification steps while maintaining adequate intermediate stability

Inventive Principle:
Principle #35Parameter changes

3Manufacturing precision

If multiple nitrogen protection/deprotection steps are implemented, then selective reaction control can be achieved, but the overall yield decreases due to the large number of process steps

Engineering Contradiction:
Improvereaction selectivityVSAvoidoverall yield
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The invention extracts and eliminates the nitrogen protection/deprotection steps that were previously necessary for reaction selectivity. By using alternative selective reagents and optimized reaction conditions, the process achieves the required manufacturing precision without the yield-penalty of multiple protection cycles

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention performs preliminary optimization of reaction conditions and reagent selection to enable selective transformations without nitrogen protection groups. This preliminary preparation of the reaction system allows subsequent steps to proceed with high selectivity and improved overall yield

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The new process simplifies the synthesis of Compound X, enhancing efficiency and yield by eliminating the need for nitrogen protection and chromatography, resulting in improved handling and manufacturing advantages.

Implementation Method 1

reducing a compound of formula (VII) under asymmetric reduction conditions to produce the compound of formula (VIIc), or a salt thereof

Methodology Applied
Scientific EffectAsymmetric reduction: Reduction

Data Source

PatentUS11414411B2Chemical process for manufacturing monobactam antibiotic and intermediates thereof
Publication Date: 2022.08.16 NOVARTIS AG
  • US11414411B2 patent drawing
  • US11414411B2 patent drawing
  • US11414411B2 patent drawing

AI summary

The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.